Drugs / Ipilimumab
Ipilimumab
also known as
Yervoy · MDX-010 · IPI · BMS-734016 · Ipilimumab(Yervoy) · MDX-CTLA4 · N01 · Yervoy (Ipilimumab) · +12 more
Monoclonal antibody targets CTLA4
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (13) | US (FDA) | YERVOY | — | 2015-10-28 – 2025-04-08 | fda.gov ↗ |
| Approved | EU (EMA) | Yervoy | — | 2011-07-13 | europa.eu ↗ |
| Approved | US (FDA) | YERVOY | — | 2011-03-25 | fda.gov ↗ |
Trials 725 · started per year
today
US approved 2011
EU approved 2011
2
5
7
6
3
6
2
2
7
9
17
37
31
33
37
53
87
79
72
56
41
38
23
22
19
28
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials | ||||||
| Phase 0 | NCT05704933 | Jun 2023 → Jun 2024 | metastatic malignant neoplasm in the brain, metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT05188118 | Feb 2023 → Feb 2025 | renal cell carcinoma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 0 | NCT05498792 | Nov 2022 → Mar 2027 expected | melanoma | Fox Chase Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT04223648 | Aug 2020 → Feb 2022 | melanoma | Yale University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT03463408 | Jul 2018 → Aug 2026 overdue | sarcoma | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03526185 | Feb 2018 → Dec 2020 | metastatic melanoma | Yale University | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT03162731 | May 2017 → Sep 2020 | head and neck carcinoma, laryngeal disorder | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT02210117 | Nov 2014 → Dec 2026 expected | clear cell renal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02113657 | Aug 2014 → Nov 2019 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01730157 | Dec 2012 → Feb 2016 | iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension, small size posterior uveal melanoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT00972933 | Dec 2009 → Jul 2013 | melanoma | Diwakar Davar | Completed | No outcome recorded |
| Phase 1184 trials · 5 met primary · 2 missed | ||||||
| Phase 1 | NCT07587827 | Nov 2026 → May 2027 expected | colorectal cancer, malignant pancreatic neoplasm | Centre Georges Francois Leclerc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07430202 | Oct 2026 → Oct 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT07501117 | Jun 2026 → Jun 2029 expected | uveal melanoma | Inge Marie Svane | Recruiting | No outcome recorded |
| Phase 1 | NCT07075120 | Apr 2026 → Aug 2027 expected | hepatocellular carcinoma | University of Hawaii | Recruiting | No outcome recorded |
| Phase 1 | NCT07401875 | Mar 2026 → Nov 2027 expected | kidney cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06968988 | Jan 2026 → Feb 2029 | soft tissue sarcoma | Washington University School of Medicine | Suspended | No outcome recorded |
| Phase 1 | NCT06324240 | Dec 2025 → Dec 2026 expected | female breast carcinoma, triple-negative breast carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 1 | NCT07134842 | Jul 2025 → Jan 2027 expected | gliosarcoma | University College, London | Recruiting | No outcome recorded |
| Phase 1 | NCT05457959 | Dec 2024 → Dec 2029 | diffuse glioma, H3 G34 mutant | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06524570 | Jul 2024 → Aug 2030 expected | metastatic malignant neoplasm | UMC Utrecht | Recruiting | No outcome recorded |
| Show all 184 trials opens the full record — a long page | ||||||
| Phase 1/2116 trials · 8 met primary · 2 missed | ||||||
| Phase 1/2 | NCT07615881 | Jul 2026 → Jul 2028 expected | melanoma | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07293351 | Mar 2026 → Nov 2029 expected | renal cell carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07291076 | Mar 2026 → Oct 2029 expected | hepatocellular carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07227415 | Feb 2026 → Nov 2027 expected | clear cell renal carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07482059 | Feb → Jun 2026 overdue | hepatocellular carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07227012 | Dec 2025 → Oct 2027 expected | hepatocellular carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06388369 | Aug 2025 → Mar 2026 | prostate cancer | University Hospital, Essen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06866262 | Aug 2025 → Aug 2031 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07121374 | Jul 2025 → Jun 2028 expected | pleural epithelioid mesothelioma | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06163820 | May 2025 → Jan 2026 overdue | metastatic melanoma | Melanoma and Skin Cancer Trials Limited | Recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 2336 trials · 18 met primary · 19 missed | ||||||
| Phase 2 | NCT07603856 | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07689175 | Oct 2026 → Oct 2031 expected | hepatocellular carcinoma | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06365619 | Oct 2026 → Aug 2027 expected | melanoma | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT07511036 | Sep 2026 → May 2028 expected | melanoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07740941 | Aug 2026 → Mar 2029 expected | cutaneous melanoma, metastatic melanoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07715565 | Aug 2026 → Dec 2029 expected | renal cell carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07645846 | Jul 2026 → Aug 2028 expected | nasal cavity and paranasal sinus carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07638631 | Jun 2026 → Dec 2028 expected | gastric cancer | Chen Lizhu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07611825 | Jun 2026 → Dec 2028 expected | renal cell carcinoma | Jinling Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07188896 | Apr 2026 → Nov 2029 expected | clear cell renal carcinoma | Brian Rini | Recruiting | No outcome recorded |
| Show all 336 trials opens the full record — a long page | ||||||
| Phase 2/37 trials · 2 missed | ||||||
| Phase 2/3 | NCT06581406 | Dec 2024 → Jan 2030 expected | uveal melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05665348 | Mar 2023 → May 2025 | hepatocellular carcinoma, metastatic malignant neoplasm | Federation Francophone de Cancerologie Digestive | Completed | Missed primary |
| Phase 2/3 | NCT05141721 | Feb 2022 → Mar 2027 expected | colorectal neoplasm | Seattle Project Corporation | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04396860 | Sep 2020 → Jan 2023 | gliosarcoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2/3 | NCT03604991 | May 2019 → Mar 2027 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2/3 | NCT03879122 | Feb 2019 → Jul 2023 | metastatic prostate carcinoma | Spanish Oncology Genito-Urinary Group | Unknown | No outcome recorded |
| Phase 2/3 | NCT03755739 | Nov 2018 → Nov 2033 expected | breast cancer, cervical cancer, colorectal cancer, head and neck cancer +6 | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 353 trials · 17 met primary · 14 missed | ||||||
| Phase 3 | NCT07166406 | Feb 2026 → Mar 2029 expected | hepatocellular carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06794775 | Jul 2025 → Apr 2032 expected | melanoma | Hildur Helgadottir | Recruiting | No outcome recorded |
| Phase 3 | NCT06490536 | Oct 2024 → Mar 2026 overdue | colorectal cancer | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06364631 | Apr 2024 → May 2032 expected | clear cell renal carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05144854 | Nov 2021 → Oct 2025 overdue | gastric cancer | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04949113 | Jul 2021 → Jan 2024 overdue | melanoma | The Netherlands Cancer Institute | Active not recruiting | Met primary |
| Phase 3 | NCT04741438 | Mar 2021 → Feb 2025 | sarcoma | Centre Leon Berard | Unknown | No outcome recorded |
| Phase 3 | NCT04340193 | Sep 2020 → Dec 2023 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT04026412 | Oct 2019 → Mar 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT04039607 | Sep 2019 → Jul 2026 overdue | hepatocellular carcinoma | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 3 | NCT04008030 | Aug 2019 → Aug 2024 overdue | colorectal cancer | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 3 | NCT03873402 | Jun 2019 → Mar 2027 expected | renal cell carcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03700905 | Aug 2018 → May 2024 | head and neck squamous cell carcinoma | University Medical Center Hamburg-Eppendorf | Unknown | No outcome recorded |
| Phase 3 | NCT03445533 | May 2018 → Jun 2021 | metastatic melanoma | Idera Pharmaceuticals, Inc. | Terminated | Missed primary |
| Phase 3 | NCT03469960 | May 2018 → Nov 2023 | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 3 | NCT03048136 | Mar 2018 → Sep 2019 | non-small cell lung carcinoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03409614 | Mar 2018 → Feb 2025 | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03351361 | Feb 2018 → Jul 2021 | non-small cell lung carcinoma | Rennes University Hospital | Completed | Missed primary |
| Phase 3 | NCT03391869 | Dec 2017 → Mar 2027 expected | lung adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03302234 | Dec 2017 → Sep 2020 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03215706 | Aug 2017 → Aug 2019 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT03141177 | Jul 2017 → Feb 2020 overdue | renal cell carcinoma | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 3 | NCT03138512 | Jul 2017 → Sep 2023 | renal cell carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT03143153 | Jun 2017 → Jan 2021 | esophageal cancer | Bristol-Myers Squibb | Completed | Mixed |
| Phase 3 | NCT03068455 | Apr 2017 → Jun 2020 | melanoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT03036098 | Mar 2017 → Aug 2024 overdue | urothelial carcinoma | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 3 | NCT02864251 | Mar 2017 → Jan 2022 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT02998528 | Mar 2017 → Sep 2021 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT02899299 | Nov 2016 → Mar 2020 | mesothelioma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT02905266 | Oct 2016 → Oct 2017 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02872116 | Oct 2016 → May 2020 | esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT02741570 | Oct 2016 → May 2021 | head and neck cancer | Bristol-Myers Squibb | Completed | Mixed |
| Phase 3 | NCT02714218 | Apr 2016 → Apr 2017 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02785952 | Dec 2015 → Dec 2019 overdue | squamous cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | Missed primary |
| Phase 3 | NCT02599402 | Dec 2015 → Feb 2020 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02545075 | Oct 2015 → Apr 2019 | melanoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT02538666 | Oct 2015 → Oct 2018 | lung cancer | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT02224781 | Sep 2015 → Sep 2023 overdue | cutaneous melanoma, metastatic melanoma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT02477826 | Aug 2015 → Oct 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | Mixed |
| Phase 3 | NCT02388906 | Mar 2015 → Nov 2018 | melanoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT02231749 | Oct 2014 → Jun 2017 | renal cell carcinoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT02279732 | Oct 2014 → May 2018 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02017717 | Feb 2014 → Jun 2019 | glioblastoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT01866319 | Aug 2013 → Mar 2015 | melanoma | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01844505 | Jun 2013 → Aug 2016 | metastatic melanoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT02460068 | Dec 2012 → Jan 2018 | metastatic malignant neoplasm in the brain | Italian Network for Tumor Biotherapy Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT01515189 | Feb 2012 → Feb 2016 | melanoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT01450761 | Dec 2011 → Mar 2015 | small cell lung carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT01274338 | Jun 2011 → Feb 2019 overdue | cutaneous melanoma | National Cancer Institute (NCI) | Active not recruiting | Mixed |
| Phase 3 | NCT01285609 | Jan 2011 → Jun 2015 | non-small cell squamous lung carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT01057810 | Jul 2010 → Apr 2015 | prostate cancer | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT00324155 | Aug 2006 → Jan 2011 | melanoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT00094653 | Sep 2004 → Aug 2009 | melanoma, metastatic neoplasm | Bristol-Myers Squibb | Completed | Met primary |
| Phase 47 trials | ||||||
| Phase 4 | NCT07574047 | Sep 2026 → Jun 2030 expected | melanoma | Swiss Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07504796 | Apr 2026 → May 2029 expected | metastatic melanoma | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT04513522 | Dec 2020 → Jan 2024 | kidney neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02982954 | Jan 2017 → May 2020 | renal cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02869789 | Oct 2016 → May 2022 | lung cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02068196 | Jan 2014 → Dec 2025 overdue | melanoma | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07233668 | Dec 2025 → Oct 2028 expected | renal cell carcinoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06353646 | Mar 2024 → Jun 2026 overdue | malignant pancreatic neoplasm | Wu Wenming | Recruiting | No outcome recorded |
| — | NCT07422779 | Mar 2022 → Mar 2027 expected | metastatic melanoma, skin cancer | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| — | NCT07428252 | Mar 2022 → Mar 2024 overdue | metastatic melanoma | Institute of Oncology Ljubljana | Active not recruiting | No outcome recorded |
| — | NCT04256213 | Jul 2020 → Aug 2021 | cervical cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| — | NCT02833233 | Jun 2016 → Jun 2024 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01701674 | Oct 2012 → Apr 2016 | metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| — | NCT01715077 | Oct 2012 → Oct 2017 | CDK4 linked melanoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT02186249 | — | melanoma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT03460782 | — | brain glioma, glioblastoma | Center Trials & Treatment | No longer available | No outcome recorded |
| — | NCT00495066 | — | melanoma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| Comparator or background therapy102 trials | ||||||
| Phase 0 | NCT05358938 Background | Jun 2022 → Oct 2024 overdue | cutaneous melanoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07838974 Background | Nov 2026 → Nov 2029 expected | melanoma | University of Southern California | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07444619 Background | Jun 2026 → Dec 2031 expected | soft tissue sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07532902 Background | Apr 2026 → Apr 2029 expected | diffused pleural mesothelioma, gastroesophageal cancer, urothelial carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07128680 Background | Mar 2026 → Aug 2028 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07176650 Comparator | Nov 2025 → Dec 2026 expected | hepatocellular carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 1 | NCT06889493 Background | May 2025 → Jun 2030 expected | neuroendocrine carcinoma | Peter Hosein, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06377111 Background | Jun 2024 → Aug 2027 expected | cutaneous melanoma | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07852325 Comparator | Jan → Dec 2024 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 1 | NCT06159101 Comparator | Nov 2023 → May 2024 | — | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT05631886 Background | Jul 2023 → Dec 2025 overdue | cancer, lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05254184 Background | Nov 2022 → Apr 2027 expected | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT05169957 Background | Aug 2022 → Jun 2023 | cutaneous melanoma, metastatic melanoma, mucosal melanoma, ocular melanoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT05303493 Background | Jun 2022 → Jul 2025 | melanoma, non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 1 | NCT04697576 Background | Oct 2021 → Sep 2027 expected | cutaneous melanoma, metastatic melanoma | Carlo Contreras | Recruiting | No outcome recorded |
| Phase 1 | NCT04868760 Comparator | May 2021 → May 2022 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03798639 Comparator | Jan 2019 → Dec 2022 | cutaneous neuroendocrine carcinoma | Claire Verschraegen | Completed | No outcome recorded |
| Phase 1 | NCT03068624 Background | Sep 2017 → Dec 2022 | metastatic malignant neoplasm, uveal melanoma | M.D. Anderson Cancer Center | Unknown | No outcome recorded |
| Phase 1 | NCT02437279 Comparator | Nov 2016 → Jun 2018 | cutaneous melanoma | The Netherlands Cancer Institute | Unknown | No outcome recorded |
| Phase 1 | NCT02935790 Background | Sep 2016 → Apr 2017 | melanoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02723006 Background | Jun 2016 → May 2018 | melanoma | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02419495 Background | Jun 2015 → Sep 2024 | cutaneous melanoma, fallopian tube carcinoma, metastatic malignant neoplasm, metastatic melanoma +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02381314 Background | Mar 2015 → Nov 2017 | melanoma, non-small cell lung carcinoma | MacroGenics | Completed | No outcome recorded |
| Phase 1 | NCT02117362 Background | May 2014 → Nov 2018 | metastatic melanoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01832870 Background | Apr 2013 → Feb 2016 | castration-resistant prostate carcinoma | Prostate Oncology Specialists, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01750580 Background | Dec 2012 → Apr 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01489059 Comparator | Dec 2011 → Jun 2014 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00803374 Background | Nov 2010 → Jul 2012 | melanoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT00586391 Background | Feb 2009 → Jul 2014 overdue | B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00796991 Comparator | Feb → Nov 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT07355205 Background | Jul 2026 → Jul 2032 expected | non-small cell lung carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07563738 Background | Mar 2026 → Sep 2029 expected | malignant pancreatic neoplasm, mesothelioma, non-small cell lung carcinoma | Orion Corporation, Orion Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05921760 Background | Oct 2023 → Nov 2024 | cancer | Servier Bio-Innovation LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT04954599 Background | May 2023 → Feb 2027 expected | cancer of unknown primary site | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05116202 Comparator | Feb 2022 → Sep 2023 | melanoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT04060407 Background | Jun 2021 → Dec 2022 | metastatic melanoma | Merck & Co., Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04665206 Background | Mar 2021 → Nov 2029 expected | mesothelioma, non-small cell lung carcinoma | Vivace Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03354962 Background | Oct 2018 → Feb 2020 | melanoma | Institut Claudius Regaud | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03400332 Background | Feb 2018 → Apr 2024 | cancer, melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT03707808 Background | Jan 2018 → Apr 2027 expected | malignant soft tissue neoplasm | University Hospital Brussels | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03009058 Background | May → Aug 2017 | metastatic malignant neoplasm | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT01689870 Background | Mar → Jun 2014 | metastatic melanoma | Ludwig Institute for Cancer Research | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01604889 Background | Mar 2012 → Dec 2016 | melanoma | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00261365 Comparator | Nov 2005 → Oct 2007 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT07510334 Background | Apr 2026 → Aug 2033 expected | clear cell renal carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06999980 Comparator | Feb 2026 → Mar 2028 expected | cutaneous melanoma, mucosal melanoma | Melanoma Institute Australia | Recruiting | No outcome recorded |
| Phase 2 | NCT06946797 Background | Sep 2025 → Feb 2027 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06250335 Background | Mar 2024 → Jan 2027 expected | refractory malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05284214 Background | Jan 2024 → Sep 2025 | cancer | Partner Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05928806 Comparator | Sep 2023 → Nov 2026 | renal cell carcinoma | Michael B. Atkins, MD | Suspended | No outcome recorded |
| Phase 2 | NCT05926960 Comparator | Jun 2023 → Feb 2026 | melanoma | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05428007 Background | Feb 2023 → Aug 2026 overdue | melanoma | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT05005273 Background | Oct → Dec 2022 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT05144529 Background | Mar 2022 → Sep 2024 | lung cancer | Eziafa Oduah, MD, PhD, MPH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04988841 Background | Jan 2022 → Aug 2024 | melanoma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT04951583 Background | Nov 2021 → Sep 2024 overdue | melanoma, non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Active not recruiting | Met primary |
| Phase 2 | NCT04899921 Background | Jun 2021 → May 2023 | metastatic melanoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04462406 Background | Feb 2021 → Jan 2027 expected | acral lentiginous melanoma, mucosal melanoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04571632 Comparator | Sep 2020 → Dec 2023 | non-small cell lung carcinoma | University Hospital Brussels | Unknown | Missed primary |
| Phase 2 | NCT04203901 Background | Jul 2020 → Sep 2023 | renal cell carcinoma | CoImmune | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04382664 Background | May 2020 → Jan 2024 | melanoma | Ultimovacs ASA | Completed | Missed primary |
| Phase 2 | NCT04090710 Comparator | Jan 2020 → Jun 2026 overdue | renal cell carcinoma | Ontario Clinical Oncology Group (OCOG) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03993379 Background | Nov 2019 → May 2020 | melanoma | CytomX Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04079166 Background | Aug 2019 → Jan 2027 expected | cutaneous melanoma | Scancell Ltd | Active not recruiting | Met primary |
| Phase 2 | NCT03340129 Comparator | Aug 2019 → Dec 2026 expected | melanoma | Melanoma Institute Australia | Recruiting | No outcome recorded |
| Phase 2 | NCT03719131 Background | Jun 2019 → Sep 2022 | cutaneous melanoma | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT03693014 Background | Oct 2018 → Oct 2026 expected | head and neck cancer, kidney cancer, lung cancer, melanoma +2 | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03070392 Comparator | Oct 2017 → Oct 2020 | uveal melanoma | Immunocore Ltd | Completed | Met primary |
| Phase 2 | NCT03071406 Comparator | Mar 2017 → Apr 2022 overdue | cutaneous neuroendocrine carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02996110 Comparator | Feb 2017 → Nov 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02553642 Background | Sep 2015 → Apr 2024 | melanoma, urinary bladder cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02374242 Comparator | Nov 2014 → Sep 2017 overdue | melanoma, metastatic malignant neoplasm in the brain | Melanoma Institute Australia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02272855 Background | Apr 2014 → Oct 2016 | melanoma | Takara Bio Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00135408 Comparator | Dec 2005 → Jul 2007 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT06624644 Comparator | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05987332 Comparator | Oct 2023 → Jan 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | Met primary |
| Phase 2/3 | NCT04929041 Background | Oct 2022 → Dec 2030 expected | adenosquamous lung carcinoma, lung adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04887870 Background | Jun 2021 → Apr 2025 | cancer of unknown primary site | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT02339571 Background | Nov 2015 → Jun 2033 expected | cutaneous melanoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07338981 Comparator | Feb 2027 → Dec 2031 expected | kidney cancer | Guliz Ozgun | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07815574 Background | Dec 2026 → Dec 2028 expected | cutaneous melanoma | Scancell Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07383441 Background | Jun 2026 → Jan 2033 expected | clear cell renal carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT06840782 Background | Sep 2025 → Feb 2030 expected | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07000149 Comparator | Jul 2025 → Feb 2030 expected | clear cell renal carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06841185 Comparator | Apr 2025 → Jun 2027 expected | hepatocellular carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06743126 Comparator | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06587451 Background | Dec 2024 → Jan 2026 | melanoma | Sandoz | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT06519266 Comparator | Jun 2024 → Dec 2028 expected | uveal melanoma | Vastra Gotaland Region | Recruiting | No outcome recorded |
| Phase 3 | NCT06097728 Comparator | Nov 2023 → Nov 2028 expected | pleural mesothelioma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04510597 Comparator | Mar 2021 → Jul 2033 expected | clear cell renal carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT04334759 Comparator | Feb 2021 → Jun 2025 | malignant pleural mesothelioma | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 3 | NCT04157985 Comparator | Nov 2019 → Oct 2025 | anal carcinoma, cervical cancer, cholangiocarcinoma, cutaneous neuroendocrine carcinoma +7 | Dan Zandberg | Completed | No outcome recorded |
| Phase 3 | NCT03937219 Background | Jun 2019 → Jan 2022 overdue | renal cell carcinoma | Exelixis | Active not recruiting | Met primary |
| Phase 3 | NCT03793166 Background | Jun 2019 → Jan 2028 expected | clear cell renal carcinoma, metastatic carcinoma in the bone, metastatic malignant neoplasm in the lymph nodes, rhabdoid tumor of the kidney +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03520686 Background | May 2018 → Oct 2025 | non-small cell lung carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02506153 Comparator | Nov 2015 → Sep 2023 overdue | cutaneous melanoma, mucosal melanoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02278887 Comparator | Sep 2014 → Sep 2022 | metastatic melanoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00861614 Comparator | May 2009 → Nov 2012 | prostate cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00636168 Comparator | Jun 2008 → Jul 2013 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT06903312 Comparator | Jun 2025 → Oct 2027 expected | renal cell carcinoma | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 4 | NCT01856023 Comparator | May 2013 → Jul 2015 | metastatic melanoma | Clinigen, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT07436390 Background | Mar 2024 | metastatic melanoma, skin cancer | Institute of Oncology Ljubljana | Completed | No outcome recorded |
Press releases naming this drug 238 releases
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 845 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ipilimumab | “The study treatment immunotherapeutic drugs (PD-1 inhibitor monoclonal antibody Keytruda (pembrolizumab), anti-CTLA-4 monoclonal antibody ipilimumab, and GM-CSF) will then be...” NCT04739618 ↗810“Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or...” NCT06903312 ↗ “vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen...” NCT03755739 ↗ “therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab, or currently approved standard of care treatment, either alone or in combination” NCT05358938 ↗ “Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.” PMID 23535954 ↗ Mar 2013 “INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.” NCT03058289 ↗ “PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma” NCT07511036 ↗ “Patients with metastatic malignant melanoma treated in the first line with combined immunotherapy with PD-1 and CTLA-4 inhibitors (ipilimumab/nivolumab).” NCT07428252 ↗ “Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.” NCT06519266 ↗ “Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations” NCT04399876 ↗ “Bavituximab 3mg/kg IVqwk (IV every week) x 14 plus ipilimumab 3mg/kg IVq3wk (IV every 3 weeks) x 4 or ipilimumab 3mg/kg IVq3wk x 4” NCT01984255 ↗ |
| Known as | BMS-734016 | “A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to...” NCT00527735 ↗6“The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients...” NCT00094653 ↗ “Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total...” NCT01449279 ↗ “The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity” NCT01302496 ↗ “ipilimumab (MDX-010, BMS-734016)” NCT00289640 ↗ “ipilimumab (MDX-010, BMS-734016)” NCT00289627 ↗ “BMS-734016” NCT02239900 ↗ |
| Known as | BMS-734016 (Ipilimumab) | “BMS-734016 (Ipilimumab)” NCT03143153 ↗1“BMS-734016 (Ipilimumab)” NCT02869789 ↗ |
| Known as | IBI310 | “Ipilimumab injection N01 (R\&D Code: IBI310) is a recombinant fully human anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody independently developed...” NCT07638631 ↗ |
| Known as | IPI | “In the MATISSE trial, the primary objective was met to investigate the pathological response rate on neoadjuvant nivolumab (NIVO) and nivolumab plus ipilimumab (NIVO + IPI) at...” PMID 41062829 ↗ Oct 202516“The phase 1/2 Intergroup study E4412 investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) combined with the CD30 targeting antibody-drug conjugate...” PMID 41662628 ↗ Apr 2026 “NRG Oncology BN002 (phase I) demonstrated safety and suggested efficacy of ipilimumab (ipi) with nivolumab (nivo) in newly diagnosed glioblastoma, leading to this phase II/III trial.” PMID 40779733 ↗ Aug 2025 “This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.” NCT06712927 ↗ “OBJECTIVE: To investigate the safety and antitumor activity of SEL, nivolumab (NIVO), and ipilimumab (IPI) in Asian patients with treatment-refractory solid organ cancers.” PMID 40502306 ↗ Jun 2025 “PURPOSE: Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma.” PMID 39504507 ↗ Nov 2024 “We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers.” PMID 38252910 ↗ Jan 2024 “Standard-of-care treatments for patients with resected stage III/IV melanoma include the immuno-oncology (IO) agents nivolumab (NIVO) and ipilimumab (IPI).” PMID 39378385 ↗ Oct 2024 “Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities” PMID 27532019 ↗ Aug 2016 “The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in CheckMate-915 did not result in increased RFS.” PMID 36450385 ↗ Nov 2022 “patients were randomized to the nivolumab plus ipilimumab arm (NIVO + IPI n = 45), or to the capecitabine arm (CT n = 50).” PMID 41314029 ↗ Nov 2025 |
| Known as | ipililumab | “Ipililumab” NCT05429866 ↗ |
| Known as | Ipilimumab (BMS-734016, MDX010, MDX-CTLA4) | “Ipilimumab (BMS-734016, MDX010, MDX-CTLA4)” NCT01740401 ↗ |
| Known as | Ipilimumab (Yervoy) BMS | “Ipilimumab (Yervoy) BMS” NCT03003637 ↗ |
| Known as | Ipilimumab(Yervoy) | “ipilimumab (Yervoy)” NCT04250246 ↗4“Ipilimumab (Yervoy)” NCT01654692 ↗ “Ipilimumab (YERVOY)” NCT02460068 ↗ “Ipilimumab (Yervoy)” NCT03026140 ↗ “Ipilimumab(Yervoy)” NCT02608437 ↗ |
| Known as | Ipilimumab-also known as MDX-010 or MDX-101 & marketed as Yervoy | “Ipilimumab-also known as MDX-010 or MDX-101 & marketed as Yervoy” NCT00790010 ↗ |
| Known as | Ipilimumab: YERVOY/ BMS-734016/ MDX-010 | “Ipilimumab: YERVOY/ BMS-734016/ MDX-010” NCT04326257 ↗ |
| Known as | MDX-010 | “We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination...” PMID 12826605 ↗ Jun 200318“A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously...” NCT00357461 ↗ “Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total...” NCT01449279 ↗ “A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.” NCT01194271 ↗ “The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity” NCT01302496 ↗ “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1.” NCT00077532 ↗ “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) and peptide vaccine” NCT00084656 ↗ “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010)” NCT00112580 ↗ “Ipilumumab (also known as MDX-010 or Yervoy)” NCT03177239 ↗ “ipilimumab (MDX-010, BMS-734016)” NCT00289640 ↗ “ipilimumab (MDX-010, BMS-734016)” NCT00289627 ↗ |
| Known as | MDX-010 MDX-CTLA4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1789844 ↗ |
| Known as | MDX-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1789844 ↗ |
| Known as | MDX-CTLA4 | “Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total...” NCT01449279 ↗2“anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4)” NCT00058279 ↗ |
| Known as | N01 | “Ipilimumab injection N01 (R\&D Code: IBI310) is a recombinant fully human anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody independently developed...” NCT07638631 ↗ |
| Known as | Yervoy | “This study will assess the highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2 (Proleukin) in patients with unresectable stages III-IV melanoma...” NCT01672450 ↗27“Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1...” NCT07121374 ↗ “The purpose of this study is to examine the safety and effectiveness (how well the drug works) of two different doses (3 mg/kg and 10 mg/kg) of Ipilimumab (Yervoy™) in patients...” NCT02279862 ↗ “Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the...” NCT02381314 ↗ “Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma” NCT02186249 ↗ “Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy .” NCT01913691 ↗ “In Norway ipilimumab (Yervoy®) has been available for treating patients with advanced, locally advanced or metastatic melanoma” NCT02068196 ↗ “Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.” NCT07176650 ↗ “Ipilimumab injection (YERVOY®), 0.3 mg/kg, administered once by intravenous infusion over 30 ± 10 minutes.” NCT07852325 ↗ “The combination of nivolumab and ipilimumab (Yervoy) is FDA approved for metastatic melanoma.” NCT03101566 ↗ “Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy” NCT07574047 ↗ |
| Known as | YERVOY (for ipilimumab) | “YERVOY (for ipilimumab)” NCT02272855 ↗ |
| Known as | Yervoy (Ipilimumab) | “Yervoy (Ipilimumab)” NCT03143153 ↗ |
| Known as | YervoyTM | “Ipilimumab (YervoyTM, BMS), a human IgG-1 anti-CTLA-4 monoclonal antibody improves the overall survival of patients with advanced melanoma” NCT03233152 ↗2“Ipilimumab (YervoyTM, 50 mg/10 mL solution)” NCT06784648 ↗ “Ipilimumab (YervoyTM, 50 mg/10 mL solution)” NCT07230613 ↗ |
| Known as | YERYOY | “Ipilimumab (YERYOY)” NCT04416568 ↗ |
| Action | Inhibit | “CTLA-4 blockade” PMID 16283570 ↗ Oct 2005 |
| Modality | Protein / enzyme biologic | “CTLA-4 antibody given intravenously” NCT00028431 ↗ |
| Route | Intravenous | “CTLA-4 antibody given intravenously” NCT00028431 ↗ |
| Target | CTLA4 | “anti-cytotoxic T-lymphocyte-associated antigen-4” NCT00039091 ↗ |